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A surgical site infection (SSI) may occur in up to 30% of procedures and results in
significant morbidity and mortality. We aimed to assess the feasibility of conduct-
ing a randomised controlled trial (RCT) examining the use of dialkylcarba-
moylchloride (DACC)-impregnated dressings, which bind bacteria at the wound bed,
in the prevention of SSI in primarily closed incisional wounds. This pilot RCT
recruited patients undergoing clean or clean-contaminated vascular surgery. Partici-
pants were randomised intraoperatively on a 1:1 basis to either a DACC-coated
dressing or a control dressing. Outcomes were divided into feasibility and clinical
outcomes. The primary clinical outcome was SSI at 30 days (assessed using Centers
for Disease Control criteria and Additional treatment, Serous discharge, Erythema,
Purulent exudate, Separation of the deep tissues, Isolation of bacteria and duration of
inpatient Stay scoring methods). This study recruited 144 patients in 12 months at a
median rate of 10 per month. Eligibility was 73% and recruitment 60%. At 30 days,
there was a 36.9% relative risk reduction in the DACC-coated arm (16.22% versus
25.71%, odds ratio 0.559, P = 0.161). The number needed to treat was 11 patients.
A large-scale RCT is both achievable and desirable given the relative risk reduction
shown in this study. Further work is needed to improve the study protocol and
involve more centres in a full-scale RCT.
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1 | INTRODUCTION
A surgical site infection (SSI) may complicate up to 40% of
vascular surgical procedures, with those undergoing lower
limb revascularisation and major limb amputations at the
highest risk.1–3 In addition to significant mortality and mor-
bidity, SSIs are known to increase length of stay by an aver-
age of 10 days and cost the National Health Service (NHS)
an estimated £700 million per annum.4 The UK National
Institute for health and Clinical Excellence and the World
Health Organisation have publishing guidelines for the pre-
vention of SSIs in recent years, which highlight the signifi-
cant scale of the problem.5–7
Postoperative wound dressings provide a stable environ-
ment for a freshly incised wound, absorbing exudate and
protecting the wound until epithelialisation can occur. Many
dressings exist and have been the subject of wound research,
yet no current systematic reviews have found evidence to
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suggest that any one dressing outperforms any other in the
prevention of SSIs.8,9
One technology not included in reviews to date is dia-
lkylcarbamoylchloride (DACC), a fatty acid derivative that
has been shown in vitro to bind to a number of pathogenic
organisms, including Pseudomonas aeruginosa and
methicillin-resistant Staphylococcus aureus (MRSA).10,11
This can be applied to dressings to irreversibly bind bacteria,
thus removing them from the wound bed.12 Evidence in var-
ious types of surgery suggests that DACC-coated dressings
show promise in the prevention of SSIs.13 Robust rando-
mised evidence is required to properly investigate the effec-
tiveness of this technology.
The aim of this pilot study was to assess the methods and
feasibility of conducting a definitive randomised clinical study
of DACC-coated dressings for the primary prevention of SSIs.
2 | METHODS
A two-arm, parallel-group, pilot feasibility randomised con-
trolled trial (RCT) was developed and conducted in a tertiary
vascular surgery unit in the United Kingdom. The full proto-
col has previously been published by the same authors.14
Ethical approval was obtained (16/LO/2135), and study con-
duct was in accordance with the Declaration of Helsinki
(1975).15 The study was prospectively registered with
clinicaltrials.gov (NCT02992951).
Patients over 18 years old, undergoing clean or clean-
contaminated vascular surgery, and capable/willing to give
informed consent were included. Those undergoing carotid
endarterectomy, receiving antibiotics at the time of surgery,
or with known allergies to trial dressings were excluded. All
eligible patients provided informed written consent.
2.1 | Outcomes
As a pilot/feasibility study, outcomes were divided into two
distinct categories: feasibility outcomes and clinical outcomes.
2.1.1 | Feasibility outcomes
• Eligibility rates and reasons for non-eligibility
• Participant recruitment rates and reasons for non-recruitment
• Follow-up and study retention rates and reasons for dro-
pout/non-attendance
• The suitability of the inclusion/exclusion criteria
• The suitability of outcome assessment measure(s)
• Fitness for purpose of follow-up arrangements
• Rates of participant withdrawal from the trial.
2.2 | Clinical outcomes
2.2.1 | Primary clinical outcome
The incidence of SSIs within 30 days of surgery, measured
by an Additional treatment, Serous discharge, Erythema,
Purulent exudate, Separation of deep tissues, Isolation of
bacteria and duration of inpatient Stay (ASEPSIS)
score ≥ 2116,17 or according to the Centers of Disease Con-
trol (CDC) definition of SSIs.18,19
2.2.2 | Secondary clinical outcomes
• The incidence of SSIs at 90 days for implant
patients only
• Satisfactory healing—total ASEPSIS score ≤ 10 at
30 days post-surgery for non-implant surgery and
implant patients
• Satisfactory healing—total ASEPSIS score ≤ 10 at
90 days post-surgery for implant patients only
2.2.3 | Randomisation, blinding, and study procedures
Participants were randomised to postoperative wound dress-
ing with either a DACC-coated occlusive absorbent dressing
(Leukomed Sorbact, BSN Medical, Hull, UK) or a non-
DACC-coated occlusive absorbent dressing (OPSITE
Post-op, Smith & Nephew, Hull, UK) in a 1:1 ratio. Rando-
misation was performed in the theatre after wound closure to
prevent performance bias using computer-generated num-
bers in random permuted blocks via an online randomisation
service (Sealed Envelope Ltd, London, UK). Randomisation
was stratified for prosthetic implant/non-implant, wound site
(upper limb/lower limb/trunk), and diabetes (yes/no).
This was an open-label trial as the differing appearances of
the dressings prevented blinding. All patients received standar-
dised care preoperatively, including surgical skin antisepsis,
antibiotic prophylaxis for all patients undergoing procedures
under general anaesthetic as per loco-regional guidance, hair
clipping, intra- and postoperative warming, and oxygen ther-
apy. Initial dressings were applied in the operating theatre under
sterile conditions. Where patients had more than one incision,
all wounds were dressed according to dressing allocation.
2.2.4 | Follow-up procedures
Follow-up visits took place between postoperative days
(POD) 5 and 7 and at POD 30 ± 3 days. Wounds were
assessed using the ASEPSIS scale16,17 by an investigator
blinded to the allocated dressing. SF-36 and the EQ-5D
Key Messages
• dialkylcarbamoylchloride (DACC)-coated dressings show
promise in the reduction of surgical site infection (SSI) in pri-
marily closed wounds, and furthermore, a large-scale rando-
mised trial would be deliverable using the methods described
in this paper
• we showed, in a randomised controlled trial of 144 patients,
that SSI was reduced by over 35%
• simple measures to improve study retention would result in a
high-quality, multicentred randomised controlled trial
884 TOTTY ET AL.
questionnaires were completed. Telephone contact with non-
attenders and postal questionnaires were completed to avoid
missing data. Further telephone contact was made at 3, 6,
and 12 months postoperatively (±2 weeks) to capture wound
problems occurring beyond POD 30.
2.3 | Statistical analysis
Data were collected and entered into IBM SPSS (IBM SPSS
Corporation, version 23; Rochester, New York), and a two-
sided P-value of <0.05 was considered the level of signifi-
cance where appropriate.
Clinical outcome data were analysed on an intention-to-
treat (ITT) basis. The groups were compared using Pearson’s
χ2 test or Fisher's exact tests for categorical data and t-tests
for continuous data. The primary outcome, presence or
absence of SSI, was compared using χ2 tests.
For the primary outcome, logistic regression analysis
was undertaken with SSI as the dependant variable and ran-
domisation group as an independent variable. The model
was adjusted for confounding variables and surgical site.
The regression model performance was assessed using the
Hosmer and Lemeshow Test.
3 | RESULTS
Recruitment commenced on the 19th January 2017 and was
completed by 7th February 2018. Patient flow through the
trial is shown in Figure 1. Tables 1 and 2 outline the baseline
characteristics, procedures performed, and intraoperative
procedures for each group.
4 | FEASIBILITY OUTCOMES
4.1 | Eligibility rate
A total of 331 patients were screened for eligibility for inclu-
sion in the study. Of these 331, 240 patients were eligible
(73%). Common reasons for ineligibility included patients
undergoing carotid surgery (35 of 91 ineligible patients,
39%) or concurrent antibiotic therapy at the time of the index
procedure (33 of 91 ineligible patients, 37%).
4.2 | Recruitment rate
Of the 240 eligible patients, 144 (60%) agreed to participate.
A variety of reasons for eligible patients not being
recruited were encountered; most commonly, patients did
not wish, or were not able, to attend follow-up visits (40 of
96 patients, 41%).
Median recruitment rate was 10 patients per month (IQR
8.25-12.75).
4.3 | Study retention, dropouts, and reasons for
withdrawal
Four patients were recruited but subsequently not rando-
mised; one patient decided not to undergo surgery, one
patient withdrew their consent to participate in the trial prior
to randomisation, one patient was not randomised because
of an error in theatres, and one patient’s procedure was
cancelled.
Sixteen patients actively withdrew from the trial during
the study period. The most common reason for withdrawal
was an inability or an unwillingness to attend study follow-
up visits (8 of 16 withdrawals).
Seven patients died in follow up, unrelated to study out-
comes or interventions, with two deaths within 30 days of
the procedure (pneumonia and myocardial infarction).
Eleven patients attended no follow-up visits and returned no
questionnaires. This amounts to a combined dropout rate of
23.6% (34 patients of 144).
4.4 | Follow-up rates and reasons for non-attendance
Of 131 possible POD 5 to 7 visits (not including patients
who had died or withdrawn from the trial), 95 were com-
pleted (73%). Of 128 possible POD 30 ± 3 visits, 81 were
completed (63%). Data on SSI within 30 days were available
for 119 participants (82.6%). Three patients withdrew from
the trial after experiencing an SSI; their data were included
in the final primary clinical outcome analysis.
4.5 | Suitability of the trial interventions
Sixteen protocol deviations related to trial interventions were
recorded. Nine patients were found have non-protocol dress-
ings in situ, with no reason given for the change. Two
patients had non-protocol dressings as their wounds required
the placement of more absorbent dressings. One patient in
the DACC arm experienced a desquamating allergic reaction
to a perioperative antibiotic, necessitating a non-adhesive
dressing to be used.
After experiencing SSIs, two patients in the control arm
had inadine applied on the wound; one patient in the control
arm had wound dressing with absorbent pads, followed by
silver nitrate dressings, and one patient in the DACC arm
had negative pressure in situ.
5 | CLINICAL OUTCOMES
5.1 | SSI within 30 days of surgery
Fewer patients in the DACC-coated group had an SSI at
30 days than the control group (12/74 (16%) and 18/70
(26%) respectively). The difference was non-significant
(P = 0.161, Pearson's χ2 test). This represents an estimated
absolute risk reduction of 10%, a relative risk reduction of
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37%, and a number needed to treat of 10.5 patients. The
crude odds ratio (OR) was 0.559 [95% CI: 0.247, 1.267].
There were no significant differences found between groups
in each surgery subtype.
Presence of diabetes, peripheral vascular disease (PVD),
and the type of surgery performed were the only factors that
had a statistically significant effect on rates of SSI. Of
30 patients who experienced an SSI, 14 had diabetes, com-
pared with 29 of 114 who did not experience an SSI
(P = 0.024). In the SSI group, 20 patients had PVD (66.7%)
versus 52 in the no SSI group (46.0%), a statistically signifi-
cant difference (P = 0.044). More patients who experienced
FIGURE 1 CONSORT diagram. DACC, dialkylcarbamoylchloride; POD, postoperative day; LTFU, lost to follow up
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SSI had lower limb arterial surgery or major limb amputa-
tions than those who did not experience SSI (56.7% and
20.0% versus 35.1% and 8.8% respectively, P = 0.029). Cur-
rent or ex-smokers were seemingly less likely to experience
infection: 14 patients of the 30 with an SSI were current or
ex-smokers (60%), in comparison with 93 of the 114 patients
without an SSI (81.6%) (P = 0.012). With regard to intrao-
perative factors, the only significant difference between the
two groups was that more patients in the SSI group had the
placement of a drain (26.7%) than in the no SSI group
(3.5%) (P < 0.001). With regard to antibiotic use, in those
who experienced SSI in the control group, 10 patients
required oral antibiotics within 30 days of their procedure,
and 7 required intravenous (IV) antibiotics. In the DACC-
coated group, seven required oral antibiotics and five IV.
5.2 | Controlling for confounding variables
A binomial logistic regression analysis was undertaken to
ascertain the effects of various factors, including dressing
group allocation, on the likelihood of experiencing SSI.
Gender, age, BMI, ASA grade 3 or higher, presence or
absence of PVD, diabetes, smoking status, procedure per-
formed, and randomisation group were included in the
model. The model explained 44.2% (Nagelkerke R2) of the
variance in SSI and correctly classified 86.7% of cases.
Table 3 summarises the results of the logistic regression
analysis.
5.3 | Satisfactory healing within 30 days of procedure
More patients achieved satisfactory healing within the first
30 days in the DACC-coated group than the control group
(62.3% versus 50.0%). The difference was non-significant
(P = 0.236, Pearson's χ2 test).
5.4 | SSI at 30 and 90 days for the implant subgroup
A total of 51 patients (35.4% of total) received a prosthetic
implant (26 patients in the DACC-coated arm, 25 in the con-
trol arm). In this group, all observed incidences of SSI
occurred between procedure and POD 30; no new infections
occurred between POD 30 and POD 90 time points. At
30 days, there was a non-significant difference in infection
rates between the two randomisation groups, with a 24.0%
infection rate in the control group, falling to 7.7% in the
intervention group (P = 0.109, Pearson's χ2 test).
TABLE 1 Baseline characteristics
Non-DACC
coated (n = 70)
DACC
coated(n = 74)
Male (n) 46 48
Female (n) 24 26
Age (yr) 62.36 (±12.31) 63.91 (±12.38)







Diet controlled 3 1
Tablet controlled 9 9
Insulin dependent 11 10
CVA (n) 8 8
Hypertension (n)
Uncontrolled 3 2
One agent 25 14
Two agents 10 22
Three or more agents 11 11
Cardiac disease (n) 28 30
PVD (n) 35 37
Respiratory disease (n) 14 16
Renal impairment (n) 16 19
Baseline creatinine
(μmol/L)
160 (±182) 152 (±198)
Procedure performed (n)
Open abdominal 14 12
Lower limb arterial 29 28




Renal dialysis access 5 8
Other 9 9
BMI, body mass index; CVA, cerebrovascular accident; DACC, dialkylcarba-
moylchloride; GI, gastrointestinal disease; PVD, peripheral vascular disease.
TABLE 2 Intraoperative details
Non-DACC
coated (n = 70)
DACC
coated (n = 74)
ASA grade








Senior StR 25 20
Junior StR 5 9
Core trainee 1 0
Other 0 0
Closure method
Continuous suture 1 3
Interrupted suture 3 10
Subcuticular suture 61 58
Skin clips 3 3
Drain placed 7 5
ASA, American Society of Anaesthesiologists; StR, specialty training registrar.
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6 | DISCUSSION
This pilot study has provided invaluable information about
the feasibility of conducting a large-scale RCT investigating
the effectiveness of DACC-coated postoperative dressings
for the prevention of SSIs. Eligibility, retention, and recruit-
ment rates were consistent with other studies in this area20,21
but could be further optimised as part of a subsequent larger
study to maximise efficiency and costs.
Despite studies of a similar scale reporting only 10% of
screened subjects recruited,22 43.5% of the patients screened
in this trial were subsequently randomised. Patients were
recruited at a median rate of 10 per month. The consistent
recruitment rate suggests it would be feasible to recruit to a
large-scale trial and provides an estimate of the number of
sites to be identified at the outset.
Patients not wishing to take part in research or patients
who were unable or unwilling to re-attend hospital for addi-
tional clinical visits made up over half of eligible patients
who were subsequently not recruited. Travel problems, and
additional appointments or costs to patients, are established
barriers to participation in clinical research.23–26 Follow-up
procedures for a larger trial would need to be augmented to
facilitate recruitment as over 40% of eligible patients not
recruited cited such problems as a reason for not entering the
trial.
Amending follow up might also impact the 20% attrition
rate seen in this pilot study. Attrition of this level may com-
promise study validity27 or alter the significance of results
depending on how missing data are handled.28 Telephone or
remote follow up is an option as only 63% of participants
attended a clinical review at POD 30 ± 3, although primary
outcome data were available for 82.6% of participants using
notes review and telephone contact. More contemporary
technology might be used during a clinical trial29 to improve
communication with patients and avoid in-person atten-
dances for follow-up data collection.30,31 Prior examples of
remote follow up are already being reported in clinical
trials,32–35 and in routine clinical practice.36–39 Specific work
aimed at identifying SSIs using remote technology is already
underway.40,41 Combining this growing area of interest with
established methods of improving follow up, such as offer-
ing incentives, may improve study recruitment and retention.
The ASEPSIS scoring system, used to identify SSIs in
post-surgical wounds, has been shown to be reliable and
related to patient outcomes.17,42,43 However, the ASEPSIS
score remains only one of a number of definitions of SSI,
and our study combined the use of ASEPSIS and CDC defi-
nitions of SSI.18,19 To achieve data that accurately reflect
true SSI rates, a combination of assessment methods, involv-
ing searching existing computerised data for GP attendances
or antibiotic prescriptions, telephone consultations, validated
questionnaire use, and targeted clinical review, should be
used.41,44,45 Several study groups are currently designing, or
validating, novel methods for the follow up of patients post-
discharge, which aim to increase the capture rate of data on
SSI in both research trials and clinical practice,41,46 and
incorporating one or more of these tools may benefit any
RCT arising as a result of this pilot study.
The effect size seen in this pilot study was a reduction in
SSI at 30 days from 26% to 16%, an ARR of 10%, and an
RRR of 36.9%. In a full-scale, two-arm RCT based on this
study design, for 90% power and 5% significance, a total of
772 participants would be required (Calculated using Open-
Epi, Open Source Epidemiologic Statistics for Public
Health47). With no adjustment to reduce attrition from near
20%, a total sample size of 925 might be required. At the
median recruitment rate of 10 participants per centre per
month, completing study recruitment in 18 months would
require approximately five centres to take part in the trial.
There are a number of clinical limitations to this study
and, therefore, any potential future studies. First, the wide
range of surgical procedures performed introduces a level of
heterogeneity into the study that may impact the results.
Although randomisation may go some way to limiting the
effects of this (by ensuring similar numbers of procedure
TABLE 3 Binomial logistic regression analysis of identified variables associated with an increase in incidence of SSI
Variable Wald df Sig OR
95% CI
Lower Upper
Gender (male) 6.187 1 0.013* 5.850 1.454 23.530
Age 0.167 1 0.682 1.010 0.963 1.060
BMI 4.765 1 0.029* 1.109 1.011 1.216
Presence of PVD 1.030 1 0.310 2.107 0.500 8.883
Current or previous smoker 7.894 1 0.005* 0.144 0.037 0.556
Presence of diabetes 0.049 1 0.824 1.131 0.381 3.360
Randomisation group 2.584 1 0.108 0.423 0.148 1.208
ASA grade ≥ 3 0.722 1 0.396 1.742 0.484 6.273
Surgical procedure performeda 6.105 1 0.013* 7.321 1.509 35.515
Placement of a Drain 6.166 1 0.013* 8.560 1.572 46.610
aSurgical procedure performed is dichotomised into infra-inguinal surgery and other vascular surgeries. *denotes statistical significance. ASA, American Society of
Anaesthesiologists; CI, confidence interval; df, degrees of freedom; OR, odds ratio; Sig, significance.
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types in each arm of the trial), future studies could focus on
a smaller group of procedures, such as those involving an
infra-inguinal incision. This may limit any bias introduced
through this heterogeneity. Second, this study was con-
ducted as an open-label study, although blinded outcome
assessors were used. Future studies could maximise the use
of blinded outcome assessors, and work is underway to vali-
date new tools that can be used in such circumstances.35,40
7 | CONCLUSIONS
As a pilot feasibility study, this study has shown that a large-
scale RCT is achievable and desirable. Amendments in the
follow-up protocol can be made to reduce the burden to
patients and improve the levels of data return. Dressings
used in this study are tolerable and showed no adverse reac-
tions. Furthermore, with an estimated relative risk reduction
of over 35%, robust evidence to support the clinical and
cost-effectiveness of DACC-coated dressings could strongly
influence current surgical practice.
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